Updated:
Primer Capital
Primer Capital is a venture capital fund investing in biotech and medical product development companies. The firm has made 17 investments, including a Seed VC...
Primer Capital
Primer Capital is a venture capital fund investing in biotech and medical product development companies. The firm has made 17 investments, including a Seed VC investment in Qymune on February 25, 2026. Primer Capital has a single portfolio exit, Acticor Biotech, which exited on November 02, 2021.
General information
Firm type
Private Equity
Year founded
2023
Location
Region
Europe
Country
Russia
City
Moscow
Corporate office
Moscow, Russia
Frequently asked questions
What sectors does Primer Capital specifically target?
Primer Capital concentrates on healthcare and life sciences, including pharmaceutical development, medical devices, and healthcare service platforms. This focused mandate distinguishes it from generalist private equity firms operating in Russia, the majority of which allocate primarily to natural resources, real estate, or consumer sectors.
What stage of companies does Primer Capital typically back?
The firm invests from early-stage venture through growth equity, often entering at points where portfolio companies require scientific diligence alongside capital. Primer Capital participates as both lead investor and syndicate partner, and its holding periods appear aligned with the long development timelines characteristic of therapeutic and medical-device businesses.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: